Aileron Therapeutics' Phase 1b trial shows LTI-03 improved biomarkers and reduced SPD levels, indicating the potential to ...

(RTTNews) - Aileron Therapeutics, Inc. (ALRN), Wednesday announced positive topline data from the cohort 2 of Phase 1b study evaluating LTI-03 in patients with idiopathic pulmonary fibrosis (IPF).

Survival rates for idiopathic pulmonary fibrosis are worse than all solid cancers except for lung and pancreatic cancer. | ...

Dr. Watanabe and his team from Niigata University have revealed that PET/CT image analysis using artificial intelligence (AI) ...

The topline data showed ISM001-055 to have improved the forced vital capacity (FVC) of IPF patients studied 12 weeks after ...

Maria L. Padilla, MD, Icahn School of Medicine at Mount Sinai, previews that experts will discuss critical management strategies for interstitial lung disease and idiopathic pulmonary fibrosis, ...

Living with IPF is never dull, says columnist Sam Kirton, who shares some updates on topics he's discussed in recent columns.

Interstitial Lung Diseases Pipeline Outlook DWN12088 is an investigational therapy for idiopathic pulmonary fibrosis (IPF), ...

They may be proverbial ‘lab rats’ but patients who participate in clinical trials are doing more than just undergoing tests – ...

The health expert has also issued advice on when you should see your GP if you have a cough that won't go away ...

A cough is a common symptom that can be caused by a number of illnesses and conditions - but in some instances you might need ...

As many Brits are falling ill with seasonal illnesses a doctor revealed how to tell what is causing your cough ...